Ardelyx Inc
Ardelyx Inc logo
ARDX

Ardelyx Inc (ARDX)

$1.721.71%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.6772
Day's Range
$1.76
$0.4902
52-Week Range
$2.19
1 month return9.55%
3 month return75.51%
1 year return39.84%
5 year return73.74%

Company Information

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
OrganizationArdelyx Inc
Employees86
CEOMr. Michael G. Raab
IndustryHealth Technology

Analyst Recommendation

based on 7 analysts ratings

Buy
57%
Buy
42%
Hold
0%
Sell

Based on 7 Wall street analysts offering stock ratings for Ardelyx Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 283.14%

Current

$1.72

Target

$6.59

Recommendation Trend

Based on 7 analyst

Current1M Ago3M Ago
Buy
4
9
9
Hold
3
4
4
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
328.1M
Book Value
$0.36
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.36
PEG Ratio
-0.08
Wall Street Target Price
6.59

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
5.16
Enterprise Value
291.5M
Enterprise Value/Revenue
32.36
Enterprise Value/Ebitda
-2.66

Technicals

Beta
1.47
50 Day MA
1.44
200 Day MA
0.99

Institutional Holdings

HHG PLC

4.4%

Vanguard Group Inc

3.06%

Woodline Partners LP

2.85%

Point72 Asset Management, L.P.

2.67%

Adage Capital Partners Gp LLC

2.13%

Ikarian Capital, LLC

1.7%

Discover more

Frequently Asked Questions

What is Ardelyx Inc share price today?

Can Indians buy Ardelyx Inc shares?

How can I buy Ardelyx Inc shares from India?

Can Fractional shares of Ardelyx Inc be purchased?

What are the documents required to start investing in Ardelyx Inc stocks?

What are today’s High and Low prices of Ardelyx Inc?

What are today’s traded volumes of Ardelyx Inc?

What is today’s market capitalisation of Ardelyx Inc?

What is the 52 Week High and Low Range of Ardelyx Inc?

How much percentage Ardelyx Inc is down from its 52 Week High?

How much percentage Ardelyx Inc is up from its 52 Week low?

What are the historical returns of Ardelyx Inc?

Who is the Chief Executive Officer (CEO) of Ardelyx Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*